focus -WSS

focus

author：comprehensive 2025-09-06 20:45:32 - browse：4

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medicare Advantage proposed rates disappoint insurers

hotspot

entertainment

WSS

The dental labor crisis is a moment of opportunity

Senators start work on Medicare physician payment reform

Senators start work on Medicare physician payment reform

Medicare threatens to cut off funding for HCA's Mission hospital

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Weight loss drugs aren’t covered by Obamacare. That may change

focus

focus

explore

United colonoscopy coverage change 'may cost lives,' doctors say

The dental labor crisis is a moment of opportunity

Affirmative action in medical school literally saved lives

'Revelatory' study finds a smoking impact that remains after quitting

How to save PrEP access — and even expand it

Vaccine advisory panel ACIP left half staffed by HHS

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A disappointing year of Humira biosimilars

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

leisure time

Robert F. Kennedy is pitching centrism on health, even on abortion

Doctors' information doesn't help them choose wisely when sick

Medicare Advantage enrollment hits roughly 33.4 million

Medicare Advantage enrollment grows 7.1% to 33.4 million people

New CMS data security rules will hurt Medicare, Medicaid research

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

hotspot

entertainment

Wikipedia

knowledge